Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
08/16/24, 12:41 PM
Location
indianapoliswalthamIndustry
pharmaceutical
manufacturing
health care
biopharma
therapeutics
biotechnology
Eli Lilly and Company has successfully completed the acquisition of Morphic Holding, Inc. This acquisition broadens Lilly's immunology pipeline, reinforcing the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology. With the addition of Morphic's oral integrin therapies, including MORF-057, Lilly aims to improve outcomes and expand treatment options for people living with inflammatory bowel disease.
Company Info
Location
Indianapolis, Indiana, United States
Company info
Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.
Unlock Strategic Intelligence with Fundz
This is just a small preview. Unlock the full dataset of company insights, strategic events, and leadership shifts — all in one platform.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.
Related people
LH
GH
DH
MH